Das, S., Russo, A. (2025). Real world treatment outcome with azacytidine (AZA)-tocilizumab (TCZ) for reducing steroid dependence in vexas syndrome with myelodysplastic syndrome (MDS): A single-center, 1.5-year longitudinal observational study. Blood. https://doi.org/10.1182/blood-2025-6695